Extended Follow-Up From MonumenTAL-1 and APP Clinical Insights on Talquetamab Efficacy Outcomes

EP: 1.Advanced Practice Decision-Making: Patient Selection and Baseline Assessment for Bispecific Therapies

EP: 2.Introducing GPRC5D and MonumenTAL-1 Trial for R/R Multiple Myeloma

Now Viewing

EP: 3.Extended Follow-Up From MonumenTAL-1 and APP Clinical Insights on Talquetamab Efficacy Outcomes

EP: 4.Updated Safety Profile of Talquetamab & Concluding Thoughts from MonumenTAL-1

The recent efficacy data from the MonumenTAL-1 trial underscore the substantial benefit of GPRC5D-directed bispecific therapy in patients with relapsed/refractory multiple myeloma. In heavily pretreated patients, including those with prior T-cell redirection, overall response rates were notably high—74% in the weekly dosing arm and 69% with every-2-week dosing. Importantly, extended follow-up presented at ASCO revealed a 36-month overall survival ranging from 45% to 61%, which is a significant achievement in a population with limited options.

Of particular interest is the difference in durability of response between the two dosing regimens. Patients receiving treatment every 2 weeks demonstrated a median duration of response of 17.5 months, compared to 9.5 months in those dosed weekly. These findings, combined with better tolerability and improved convenience for patients, have led many centers to adopt the biweekly dosing schedule as standard. The extended dosing not only supports a strong efficacy profile but also helps preserve patient quality of life by reducing clinic visits and minimizing cumulative toxicity.

Clinical experience has shown that most adverse events, particularly those associated with GPRC5D expression in keratinized tissues, tend to appear early in treatment, often within the first cycle. As a result, some dose holds may be required early on, but the overall safety profile has proven manageable. The favorable balance of efficacy, durability, and tolerability positions this bispecific antibody as a valuable tool in managing advanced myeloma. While a cure remains elusive, this therapy contributes meaningfully to transforming myeloma into a chronic disease, offering patients longer, more stable lives with fewer treatment-related disruptions.